Consequence of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 1946-1949

  Bosso, John A ^a,b,e   Mauldin, Patrick D ^a,c,d   Steed, Lisa L ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Center for Medication Safety   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antibiogram; Pseudomonas aeruginosa; Resistance; Susceptibility

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DRUG CHOICE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; COMPARATIVE STUDY; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; STANDARD; STATISTICS; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 33751007875     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H377     Document Type: Article

References (8)

1. Høiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr Scand 1982;301(suppl):33-54.
2. Westbrock-Wadman S, Sherman DR, Hickey MJ, et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999;43:2975-83.
3. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003;426:306-10.
4. Sriramulu DD, Lunsdorf H, Lam JS, Romling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol 2005;54:667-76.
5. Macia MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005;49:3382-6.
6. Performance standards for antimicrobial disk susceptibility tests; approved guideline. 8th ed. NCCLS document M2-A8. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003.
7. Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline. NCCLS document M39-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
8. White RL, Friedrich LV, Mihm LB, Bosso JA, Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient care areas. Clin Infect Dis 2000;31:16-23.